#Denmark #Lundbeck #bexicaserin #Valby #Epilepsy Congress

Lundbeck to Highlight Mechanistic Insights on Bexicaserin

Lundbeck, a biopharmaceutical company renowned for its focus on brain health, has announced a significant development in the field of epilepsy treatment. At the upcoming European Epilepsy Congress in Athens, taking place from September 5 to 9, 2026, Lundbeck will share preclinical research that delves into the dual mode of action of bexicaserin, an investigational oral superagonist of the 5-HT2C receptor. This presentation is especially exciting as it may pave the way for novel treatment options for patients suffering from diverse and severe types of epilepsy, particularly Developmental and Epileptic Encephalopathies (DEEs).

Understanding Bexicaserin’s Mechanisms

The latest preclinical data reveal that bexicaserin functions by maximizing inhibitory activity while minimizing excitatory neuronal responses. This intricate balance is crucial as it suggests a broader antiseizure efficacy in various preclinical models representing focal, generalized motor, and absence seizures across multiple etiologies. Tarek Samad, Executive Vice President of Research and Development at Lundbeck, expressed enthusiasm regarding the findings, emphasizing the dire need for new alternatives in treating DEEs, which are characterized by heterogeneous symptoms and are resistant to current therapies.

DEEs encompass a range of rare epilepsy syndromes, often manifesting in early childhood, accompanied. They cause severe impairment, frequent seizures, and developmental regression, underscoring an urgent demand for innovative therapeutic strategies. Currently, there are no existing antiseizure medications approved specifically for all DEE types.

Presentation Highlights at the Congress

During the congress, Lundbeck's contributions will not only focus on the preclinical insights of bexicaserin but also include clinical data from its extensive development program. One of the key oral presentations will outline the significant findings on bexicaserin's impact on neuronal circuits, demonstrating its potential effects across various seizure types and their differing underlying causes.

The detailed schedule for Lundbeck’s presentations includes:

• - Analysis of bexicaserin’s effects on DEE treatments and response rates during clinical trials.
• - Insights from an expanded access program focusing on long-term efficacy in patients undergoing treatment for up to two years.
• - Observations on how bexicaserin modulates neural circuits in models of Sudden Unexpected Death in Epilepsy (SUDEP).

The DEEp Program

Bexicaserin is currently undergoing evaluation in a global Phase III DEEp Program, targeting seizure management in those with developmental and epileptic encephalopathies. The program includes two main trials: DEEp OCEAN, which investigates bexicaserin's effectiveness for patients including those with Lennox-Gastaut syndrome, and DEEp SEA, aimed at individuals with Dravet syndrome. Both trials promise to provide valuable data on the drug’s safety and its ability to reduce seizure frequency.

Conclusion

Lundbeck's ongoing commitment to neurological research is evident in its pursuit of innovative treatments for challenging conditions like DEEs. As the company prepares for the European Epilepsy Congress, the anticipation builds around the potential of bexicaserin to alter the landscape of treatment options for epilepsy, especially for those suffering from conditions marked by a lack of effective therapies. Lundbeck’s dedication serves as a beacon for those affected by these debilitating disorders, promoting hope and highlighting the significant advancements in epilepsy research.

For further information, readers can explore Lundbeck's ongoing research and upcoming presentations that promise to challenge existing paradigms in epilepsy treatment and increase understanding of the underlying mechanisms.